Martens M G, Faro S, Hammill H A, Smith D, Riddle G, Maccato M
Department of Obstetrics-Gynecology, Baylor College of Medicine, Houston, Texas 77030.
Diagn Microbiol Infect Dis. 1989 Jul-Aug;12(4 Suppl):189S-194S. doi: 10.1016/0732-8893(89)90135-1.
Sixty-seven patients diagnosed with post-cesarean-section endometritis were studied in a prospective comparative randomized trial of sulbactam/ampicillin, a new beta-lactamase inhibitor drug combination, versus treatment with metronidazole/gentamicin. The success rate was 91% for each antibiotic regimen. Mycoplasma spp. or Ureaplasma spp. were isolated from all treatment failures. Endometrial cultures revealed 2.3 aerobes as well as anaerobes per patient, with Enterococcus faecalis, Bacteroides bivius, and Escherichia coli the most frequently reported bacterial isolates in 64, 40, and 28% of all patients, respectively. Positive blood cultures were noted in 11 (15%) patients with Mycoplasma sp. the most commonly found isolate (45.5%). Sulbactam/ampicillin appears to be safe and equally effective as a metronidazole/aminoglycoside drug regimen in the treatment of postpartum endometritis.
在一项前瞻性比较随机试验中,对67例诊断为剖宫产术后子宫内膜炎的患者进行了研究,比较了新型β-内酰胺酶抑制剂药物组合舒巴坦/氨苄西林与甲硝唑/庆大霉素治疗的效果。每种抗生素治疗方案的成功率均为91%。所有治疗失败的病例均分离出支原体属或脲原体属。子宫内膜培养显示,每位患者的需氧菌和厌氧菌平均为2.3种,粪肠球菌、双栖拟杆菌和大肠杆菌分别是64%、40%和28%的所有患者中最常报告的细菌分离株。11例(15%)患者血培养呈阳性,支原体属是最常见的分离株(45.5%)。在治疗产后子宫内膜炎方面,舒巴坦/氨苄西林似乎与甲硝唑/氨基糖苷类药物治疗方案一样安全且疗效相当。